{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380021391884114054.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Cecilia Hale"}],"foaf:familyName":[{"@value":"Hale"}],"foaf:givenName":[{"@value":"Cecilia"}]}],"career":[{"institution":{"notation":[{"@value":"Alnylam Pharmaceuticals, Cambridge, MA, USA"}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360021391884114048","@type":"Article","resourceType":"学術雑誌論文(journal article)","productIdentifier":[{"@type":"DOI","@value":"10.1080/13506129.2023.2232520"},{"@type":"URI","@value":"https://www.tandfonline.com/doi/pdf/10.1080/13506129.2023.2232520"},{"@type":"DOI","@value":"10.6084/m9.figshare.23715676.v1"},{"@type":"DOI","@value":"10.6084/m9.figshare.23715676"},{"@type":"PMID","@value":"37563759"}],"notation":[{"@value":"Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1080/13506129.2023.2232520_ICwYE5mb6az8Ot2K0jeqlBjuxSm"},{"@type":"OPENAIRE","@value":"doi_dedup___::7fdebc30985cf1024ccaa497508c85b3_ICwYE5mb6az8Ot2K0jeqlBjuxSm"}]}